search
Back to results

The Genital Microbiome of Male Partners of Women With Recurrent BV Undergoing Vaginal Microbiome Transplantation

Primary Purpose

Bacterial Vaginosis, Microbial Colonization

Status
Recruiting
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
chlorhexidine gluconate 4%
Sponsored by
Hadassah Medical Organization
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Bacterial Vaginosis focused on measuring Penile microbiome, Vaginal microbiome transplant, Male partners, Bacterial vaginosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria: The subject has s female partner who participates in VMT study ( NCT04517487). The subject is defined by the woman as her male regular partner. Willing to use a condom as instructed by the protocol. Willing to comply with decolonization protocol. Exclusion Criteria: A known skin disease involving the penile skin. A known sensitivity to chlorhexidine gluconate Any of the partners (female/male) has more than one sexual partner.

Sites / Locations

  • Hadassah Medical CenterRecruiting

Outcomes

Primary Outcome Measures

Penile microbiome composition
Characterization of the penile microbial communities using shotgun analysis, and their similarity to the vaginal microbiota composition of their sexual partner.
Penile microbiome composition after disinfection
Characterization of the penile microbiome composition using shotgun analysis, after disinfection protocol or antibiotic use.

Secondary Outcome Measures

Full Information

First Posted
July 17, 2023
Last Updated
July 26, 2023
Sponsor
Hadassah Medical Organization
search

1. Study Identification

Unique Protocol Identification Number
NCT05963711
Brief Title
The Genital Microbiome of Male Partners of Women With Recurrent BV Undergoing Vaginal Microbiome Transplantation
Official Title
The Penile Microbiome in Partners of Women With Recurrent BV and Its Response to Decolonization Protocol
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 17, 2022 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
June 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hadassah Medical Organization

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
There is strong observational evidence that sexual activity plays a key role in Bacterial Vaginosis (BV) acquisition and recurrence. Microbiological data support the contribution of sexual transmission to the pathogenesis of BV through the exchange of BV-associated bacteria (BVAB) between sexual partners. Although BV epidemiology strongly suggests sexual transmission, treatment of sexual partners is not recommended, based on prior treatment studies of male partners of women with recurrent BV, which showed no benefit with male treatment. Nevertheless, male condom use is highly protective against recurrent BV. This study aims to evaluate the male-partner's genital microbiome as a potential source of BV-recurrence in women undergoing vaginal microbiota transplantation (NCT04517487), and whether disinfection can eliminate BV-associated penile microbiome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bacterial Vaginosis, Microbial Colonization
Keywords
Penile microbiome, Vaginal microbiome transplant, Male partners, Bacterial vaginosis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
In those with BV-associated penile microbiome, a decolonization attempt will be conducted, (daily wash for 5 days with chlorhexidine gluconate 4%). if decolonization fails, an antibiotic cream will be used to eradicate BV associated bacteria.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Other
Intervention Name(s)
chlorhexidine gluconate 4%
Other Intervention Name(s)
2% clindamycin cream
Intervention Description
In case BV associated bacteria will be identified (using molecular sequencing) in male samples, decolonization attempt will be conducted, using a daily wash for 5 days with chlorhexidine gluconate 4%. Following decolonization attempt, male participants will undergo re- sampling, to assess for microbiome changes. In case there is no change in microbial composition, partners will be instructed to repeat decolonization protocol, and apply a 2 cm diameter volume of 2% clindamycin cream topically to the head of the penis and upper shaft (under the foreskin if uncircumcised) twice daily for seven days following repeated decolonization. Re-sampling will follow.
Primary Outcome Measure Information:
Title
Penile microbiome composition
Description
Characterization of the penile microbial communities using shotgun analysis, and their similarity to the vaginal microbiota composition of their sexual partner.
Time Frame
1 year
Title
Penile microbiome composition after disinfection
Description
Characterization of the penile microbiome composition using shotgun analysis, after disinfection protocol or antibiotic use.
Time Frame
1 year

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The subject has s female partner who participates in VMT study ( NCT04517487). The subject is defined by the woman as her male regular partner. Willing to use a condom as instructed by the protocol. Willing to comply with decolonization protocol. Exclusion Criteria: A known skin disease involving the penile skin. A known sensitivity to chlorhexidine gluconate Any of the partners (female/male) has more than one sexual partner.
Facility Information:
Facility Name
Hadassah Medical Center
City
Jerusalem
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ahinoam Lev Sagie, MD
Phone
+972-54-4327178
Email
levsagie@netvision.net.il

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Genital Microbiome of Male Partners of Women With Recurrent BV Undergoing Vaginal Microbiome Transplantation

We'll reach out to this number within 24 hrs